Immunotherapy for the Treatment of Advanced Solid Tumor


Tongji Hospital

Status and phase

Phase 2
Phase 1


Solid Tumor
Metastatic Cancer
Recurrence Tumor


Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: TIL

Study type


Funder types




Details and patient eligibility


The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes (TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.

Full description

Adoptive cell transfer therapy that utilizes an autologous TIL manufacturing progress is originally developed by the NCI for the treatment of patients with recurrent, metastatic cervical cancer and liver cancer. TILs specific to personalized neo-antigens will be expended in vitro and given back to the patients through vein. A total of 20 patients will be enrolled in the single-arm, open label, interventional study.


40 estimated patients




18 to 70 years old


No Healthy Volunteers

Inclusion criteria

To be eligible for the study, patients must meet ALL of the following criteria prior to enrollment in the study:

  • Must be ≥ 18 years of age at the time of consent.
  • Must have recurrent, metastatic, or persistent carcinoma that is not amenable to curative treatment with surgery and/or radiation therapy and for which no other therapies are expected to have significant benefit, in the opinion of the Investigator.
  • Must have at least 1 lesion that is resectable for TIL generation. The resected TIL generating lesion(s) should yield at least 1.5 cm in diameter post-resection of tumor tissue. Following resection for TIL generation, must have a remaining measurable target lesion as defined by RECIST v1.1.
  • Patients must have progressive disease while receiving or after the completion of the most recent prior treatment.
  • Any prior therapy directed at the malignant tumor must be discontinued at least 28 days prior to tumor resection. Radiation therapy may have been received up to 28 days prior to tumor resection for lesions not expected to be used for TIL generation or target lesions.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Patients must be seronegative for the human immunodeficiency virus (HIV).
  • Patients with positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or hepatitis C virus (anti-HCV) indicating acute or chronic infection may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment.


Absolute neutrophil count greater than 1000/mm(3) without the support of filgrastim;White blood cell (WBC) greater than or equal to 3000/mm(3);Platelet count greater than or equal too 100,000/mm(3);Hemoglobin greater than 8.0 g/dl.


Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than or equal to to 2.5 times the upper limit of normal. Serum creatinine less than or equal to to 1.6 mg/dl.Total bilirubin less that or equal to 1.5 mg/dl, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.

Women of child bearing potential must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.

Exclusion criteria

  • Patients who have received an organ allograft or prior cell transfer therapy.
  • Patients who are on a systemic steroid therapy > 10 mg of prednisone daily or other steroid equivalent.
  • Patients who currently have prior therapy-related toxicities greater than Grade 1 according to NCI-CTCAE v4.03; except for peripheral neuropathy, alopecia, or vitiligo prior to enrollment/resection.
  • Patients who have a contraindication to or history of hypersensitivity reaction to any component or excipients of the TIL therapy and the other study drugs.
  • Patients with active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory, or immune system.
  • Patients with symptomatic and/or untreated brain metastases (of any size and any number).
  • Patients who have any form of primary or acquired immunodeficiency syndrome, such as severe combined immunodeficiency disease or acquired immune deficiency syndrome (AIDS).
  • Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis.

Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New York Heart Association (NYHA) Class 2 or higher.

Patients who have a forced expiratory volume in 1 second (FEV1) of less than or equal to 60% of predicted normal.

  • Patients who have received a live or attenuated vaccine within 28 days of the NMA-LD regimen.
  • Patients whose cancer requires immediate treatment or who would otherwise suffer a disadvantage by participating in this study.
  • Patients who have received prior treatment with immunotherapy (eg, anti-PD-1 anti-PD-L1, or anti-CTLA4 antibodies)

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

40 participants in 1 patient group

Experimental group
Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine). Drug: Aldesleukin 125,000 IU/kg IV/day (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr. Drug: Fludarabine Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
Biological: TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

Trial contacts and locations



Central trial contact

Zhiyong Huang, MD; Hui Wang, MD

Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems